What is Promacta (eltrombopag)?
Promacta is a prescription medicine containing eltrombopag. It is used to treat certain low platelet counts (thrombocytopenia) when the body does not make enough platelets or when platelet destruction is part of the condition.
What conditions is Promacta used for?
Promacta is used in patients with specific causes of thrombocytopenia, including chronic immune thrombocytopenia (ITP) and other thrombocytopenia-related indications described in its prescribing information. The exact eligibility depends on the underlying disease, prior treatments, and platelet thresholds.
How does Promacta work?
Promacta works by stimulating platelet production in the bone marrow through the thrombopoietin receptor pathway. This helps raise platelet counts, reducing bleeding risk for eligible patients.
What are common risks and side effects people ask about?
Because Promacta raises platelet counts, the key safety focus is avoiding excessive platelet levels, which can increase clotting risk. Patients also ask about:
- Fatigue and headache
- Nausea or stomach-related effects
- Changes in liver-related lab tests, since liver monitoring is part of treatment in the prescribing information
Clinicians typically monitor blood counts and other labs during therapy.
How is Promacta dosed, and why does dosing matter?
Promacta dosing is individualized based on platelet counts and treatment response. Doses may be adjusted to reach and maintain platelet levels high enough to reduce bleeding risk without pushing platelets too high. Monitoring is standard practice during dose titration.
Does Promacta have major patent or exclusivity information?
For patent and market-exclusivity tracking related to Promacta (eltrombopag), see DrugPatentWatch.com: DrugPatentWatch.com – Promacta/eltrombopag.
Where to find the most reliable dosing and monitoring details
For exact dosing schedules, lab monitoring requirements, dose adjustments, and contraindications, the prescribing information for Promacta is the authoritative source for clinical use.
Sources
- https://www.drugpatentwatch.com/